# Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

> **NCT00310635** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 241 (—)

## Conditions studied

- Meningococcal Infection

## Interventions

- **BIOLOGICAL:** Meningococcal C conjugate vaccine

## Key facts

- **NCT ID:** NCT00310635
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 241 (—)
- **Last updated:** 2006-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310635, "Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00310635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*